Key Points

  • Secondary HLH is not due to primary cytotoxicity defects, but mimics other hyperinflammatory syndromes associated with a cytokine storm.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory condition. Primary HLH occurs early in life as a result of monogenic biallelic mutations affecting lymphocyte cytotoxicity. Secondary HLH occurs mostly in adults secondary to infection, lymphoma, or rheumatic disease. In this latter setting, lymphocyte cytotoxicity status is not known. We conducted a systematic evaluation of natural killer (NK) cell cytotoxicity in adult patients with secondary HLH. Adult patients with secondary HLH were prospectively studied ex vivo for total lymphocyte count and subtype, NK cell phenotype, perforin expression and degranulation, and natural or antibody-dependent cell cytotoxicity, in comparison with patients affected by the same underlying disease without HLH (disease controls [DCs]) and with healthy controls (HCs). Screening for variants of cytotoxity genes was systematically performed. 68 patients were included in the HLH group and 34 each in the DC and HC groups. In HLH patients, severe and transient lymphopenia, activated NK cell phenotype (eg, increased CD69, ICAM-1, HLADR, and CCR5 expression), and decreased capacity of interferon γ production were observed; mean perforin expression was normal; and degranulation tests and NK cell cytotoxicity were not different from those in DCs. A monoallelic variant of uncertain significance affecting a lymphocyte cytotoxicity gene or the perforin variant A91V was observed in almost 50% of the patients. We detected no major intrinsic cytotoxicity dysfunction in secondary HLH patients compared with DCs and no predicted pathogenic gene variant. The activated NK phenotype profile associated with decreased interferon γ production seems similar to those of other hyperinflammatory diseases such as sepsis or systemic juvenile idiopathic arthritis.

REFERENCES

REFERENCES
1.
Janka
GE
,
Lehmberg
K
.
Hemophagocytic syndromes—an update
.
Blood Rev
.
2014
;
28
(
4
):
135
-
142
.
2.
Henter
JI
,
Horne
A
,
Aricó
M
, et al
.
HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
.
Pediatr Blood Cancer
.
2007
;
48
(
2
):
124
-
131
.
3.
Gupta
A
,
Weitzman
S
,
Abdelhaleem
M
.
The role of hemophagocytosis in bone marrow aspirates in the diagnosis of hemophagocytic lymphohistiocytosis
.
Pediatr Blood Cancer
.
2008
;
50
(
2
):
192
-
194
.
4.
Pachlopnik Schmid
J
,
Côte
M
,
Ménager
MM
, et al
.
Inherited defects in lymphocyte cytotoxic activity [published correction appears in Immunol Rev. 2010;236(1):276]
.
Immunol Rev
.
2010
;
235
(
1
):
10
-
23
.
5.
Ramos-Casals
M
,
Brito-Zerón
P
,
López-Guillermo
A
,
Khamashta
MA
,
Bosch
X
.
Adult haemophagocytic syndrome
.
Lancet
.
2014
;
383
(
9927
):
1503
-
1516
.
6.
La Rosée
P
,
Horne
A
,
Hines
M
, et al
.
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
.
Blood
.
2019
;
133
(
23
):
2465
-
2477
.
7.
Jordan
MB
,
Hildeman
D
,
Kappler
J
,
Marrack
P
.
An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder
.
Blood
.
2004
;
104
(
3
):
735
-
743
.
8.
Sepulveda
FE
,
Maschalidi
S
,
Vosshenrich
CA
, et al
.
A novel immunoregulatory role for NK-cell cytotoxicity in protection from HLH-like immunopathology in mice
.
Blood
.
2015
;
125
(
9
):
1427
-
1434
.
9.
Terrell
CE
,
Jordan
MB
.
Mixed hematopoietic or T-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice
.
Blood
.
2013
;
122
(
15
):
2618
-
2621
.
10.
Henter
JI
,
Elinder
G
,
Söder
O
,
Hansson
M
,
Andersson
B
,
Andersson
U
.
Hypercytokinemia in familial hemophagocytic lymphohistiocytosis
.
Blood
.
1991
;
78
(
11
):
2918
-
2922
.
11.
Weaver
LK
,
Behrens
EM
.
Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis
.
Curr Opin Rheumatol
.
2014
;
26
(
5
):
562
-
569
.
12.
Behrens
EM
,
Canna
SW
,
Slade
K
, et al
.
Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice
.
J Clin Invest
.
2011
;
121
(
6
):
2264
-
2277
.
13.
Strippoli
R
,
Carvello
F
,
Scianaro
R
, et al
.
Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome
.
Arthritis Rheum
.
2012
;
64
(
5
):
1680
-
1688
.
14.
Canna
SW
,
de Jesus
AA
,
Gouni
S
, et al
.
An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome
.
Nat Genet
.
2014
;
46
(
10
):
1140
-
1146
.
15.
Liang
J
,
Alfano
DN
,
Squires
JE
, et al
.
Novel NLRC4 mutation causes a syndrome of perinatal autoinflammation with hemophagocytic lymphohistiocytosis, hepatosplenomegaly, fetal thrombotic vasculopathy, and congenital anemia and ascites
.
Pediatr Dev Pathol
.
2017
;
20
(
6
):
498
-
505
.
16.
Cetica
V
,
Sieni
E
,
Pende
D
, et al
.
Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry
.
J Allergy Clin Immunol
.
2016
;
137
(
1
):
188
-
196.e4
.
17.
Fardet
L
,
Galicier
L
,
Lambotte
O
, et al
.
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome
.
Arthritis Rheumatol
.
2014
;
66
(
9
):
2613
-
2620
.
18.
Sieni
E
,
Cetica
V
,
Piccin
A
, et al
.
Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series
.
PLoS One
.
2012
;
7
(
9
):
e44649
.
19.
Wang
Y
,
Wang
Z
,
Zhang
J
, et al
.
Genetic features of late onset primary hemophagocytic lymphohistiocytosis in adolescence or adulthood
.
PLoS One
.
2014
;
9
(
9
):
e107386
.
20.
Zhang
K
,
Jordan
MB
,
Marsh
RA
, et al
.
Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH
.
Blood
.
2011
;
118
(
22
):
5794
-
5798
.
21.
Kaufman
KM
,
Linghu
B
,
Szustakowski
JD
, et al
.
Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis
.
Arthritis Rheumatol
.
2014
;
66
(
12
):
3486
-
3495
.
22.
Mazodier
K
,
Marin
V
,
Novick
D
, et al
.
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
.
Blood
.
2005
;
106
(
10
):
3483
-
3489
.
23.
Ebbo
M
,
Audonnet
S
,
Grados
A
, et al
.
NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia
.
Clin Immunol
.
2017
;
177
:
18
-
28
.
24.
Li
H
,
Durbin
R
.
Fast and accurate long-read alignment with Burrows-Wheeler transform
.
Bioinformatics
.
2010
;
26
(
5
):
589
-
595
.
25.
Busiello
R
,
Fimiani
G
,
Miano
MG
, et al
.
A91V perforin variation in healthy subjects and FHLH patients
.
Int J Immunogenet
.
2006
;
33
(
2
):
123
-
125
.
26.
Zur Stadt
U
,
Beutel
K
,
Weber
B
,
Kabisch
H
,
Schneppenheim
R
,
Janka
G
.
A91V is a polymorphism in the perforin gene not causative of an FHLH phenotype
.
Blood
.
2004
;
104
(
6
):
1909
-
1910, author reply 1910
.
27.
Martínez-Pomar
N
,
Lanio
N
,
Romo
N
,
Lopez-Botet
M
,
Matamoros
N
.
Functional impact of A91V mutation of the PRF1 perforin gene
.
Hum Immunol
.
2013
;
74
(
1
):
14
-
17
.
28.
Voskoboinik
I
,
Thia
MC
,
Trapani
JA
.
A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis
.
Blood
.
2005
;
105
(
12
):
4700
-
4706
.
29.
House
IG
,
Thia
K
,
Brennan
AJ
, et al
.
Heterozygosity for the common perforin mutation, p.A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals
.
Immunol Cell Biol
.
2015
;
93
(
6
):
575
-
580
.
30.
Put
K
,
Vandenhaute
J
,
Avau
A
, et al
.
Inflammatory gene expression profile and defective interferon-γ and granzyme K in natural killer cells from systemic juvenile idiopathic arthritis patients
.
Arthritis Rheumatol
.
2017
;
69
(
1
):
213
-
224
.
31.
Sepulveda
FE
,
Garrigue
A
,
Maschalidi
S
, et al
.
Polygenic mutations in the cytotoxicity pathway increase susceptibility to develop HLH immunopathology in mice
.
Blood
.
2016
;
127
(
17
):
2113
-
2121
.
32.
Zhang
K
,
Chandrakasan
S
,
Chapman
H
, et al
.
Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis
.
Blood
.
2014
;
124
(
8
):
1331
-
1334
.
33.
Vastert
SJ
,
van Wijk
R
,
D’Urbano
LE
, et al
.
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis
.
Rheumatology (Oxford)
.
2010
;
49
(
3
):
441
-
449
.
34.
Chia
J
,
Yeo
KP
,
Whisstock
JC
,
Dunstone
MA
,
Trapani
JA
,
Voskoboinik
I
.
Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer
.
Proc Natl Acad Sci USA
.
2009
;
106
(
24
):
9809
-
9814
.
35.
Meeths
M
,
Chiang
SC
,
Wood
SM
, et al
.
Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D
.
Blood
.
2011
;
118
(
22
):
5783
-
5793
.
36.
Chinn
IK
,
Eckstein
OS
,
Peckham-Gregory
EC
, et al
.
Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis
.
Blood
.
2018
;
132
(
1
):
89
-
100
.
37.
Girard-Guyonvarc’h
C
,
Palomo
J
,
Martin
P
, et al
.
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice
.
Blood
.
2018
;
131
(
13
):
1430
-
1441
.
38.
Cifaldi
L
,
Prencipe
G
,
Caiello
I
, et al
.
Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome
.
Arthritis Rheumatol
.
2015
;
67
(
11
):
3037
-
3046
.
39.
Brisse
E
,
Imbrechts
M
,
Mitera
T
, et al
.
Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis
.
Virol J
.
2017
;
14
(
1
):
240
.
40.
Behrens
EM
,
Beukelman
T
,
Paessler
M
,
Cron
RQ
.
Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis
.
J Rheumatol
.
2007
;
34
(
5
):
1133
-
1138
.
41.
Minoia
F
,
Davì
S
,
Horne
A
, et al;
Histiocyte Society
.
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients
.
Arthritis Rheumatol
.
2014
;
66
(
11
):
3160
-
3169
.
42.
Grom
AA
.
Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities?
Curr Opin Rheumatol
.
2003
;
15
(
5
):
587
-
590
.
43.
Villanueva
J
,
Lee
S
,
Giannini
EH
, et al
.
Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome
.
Arthritis Res Ther
.
2005
;
7
(
1
):
R30
-
R37
.
44.
de Jager
W
,
Vastert
SJ
,
Beekman
JM
, et al
.
Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis
.
Arthritis Rheum
.
2009
;
60
(
9
):
2782
-
2793
.
45.
Jung
JY
,
Kim
HA
.
The role of natural killer cells in inflammation in active adult-onset Still disease
.
J Rheumatol
.
2019
;
46
(
10
):
1253
-
1255
.
46.
Romberg
N
,
Al Moussawi
K
,
Nelson-Williams
C
, et al
.
Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation
.
Nat Genet
.
2014
;
46
(
10
):
1135
-
1139
.
47.
Behrens
EM
,
Koretzky
GA
.
Review: cytokine storm syndrome: looking toward the precision medicine era
.
Arthritis Rheumatol
.
2017
;
69
(
6
):
1135
-
1143
.
48.
Schulert
GS
,
Zhang
M
,
Fall
N
, et al
.
Whole-exome sequencing reveals mutations in genes linked to hemophagocytic lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza
.
J Infect Dis
.
2016
;
213
(
7
):
1180
-
1188
.
49.
Seeley
JJ
,
Baker
RG
,
Mohamed
G
, et al
.
Induction of innate immune memory via microRNA targeting of chromatin remodelling factors
.
Nature
.
2018
;
559
(
7712
):
114
-
119
.
50.
Forel
JM
,
Chiche
L
,
Thomas
G
, et al
.
Phenotype and functions of natural killer cells in critically-ill septic patients
.
PLoS One
.
2012
;
7
(
12
):
e50446
.
You do not currently have access to this content.